| Company | Date | Position | Consensus β | Price Target β | 2-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
PROK
ProKidney
|
Oct 27, 2026 | SELL |
Buy
+393.1% avg upside
12 analysts
|
$1.00
34.29% Downside
|
+30.5% | Β· |
|
VERA
Vera Therapeutics
|
Oct 23, 2026 | BUY |
Strong Buy
+114.1% avg upside
19 analysts
|
$60.00
93.98% Upside
|
+0.4% | Β· |
|
IMVT
Immunovant
|
Oct 12, 2026 | BUY |
Strong Buy
+38.4% avg upside
25 analysts
|
$45.00
52.92% Upside
|
+16.7% | Β· |
|
BHVN
Biohaven Ltd.
|
Oct 12, 2026 | SELL |
Buy
+51.3% avg upside
25 analysts
|
$11.00
29.12% Downside
|
-17.0% | Β· |
|
AMLX
Amylyx Pharmaceuticals Inc
|
May 07, 2026 | BUY |
Strong Buy
+31.6% avg upside
14 analysts
|
$22.00
21.57% Downside
|
+50.1% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.